H.C. Wainwright Upgrades Ocular Therapeutix (OCUL) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts OCUL Hot Sheet
Price: $7.10 +4.11%
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
H.C. Wainwright analyst Yi Chen upgraded Ocular Therapeutix (NASDAQ: OCUL) from Neutral to Buy with a price target of $17.00.
For an analyst ratings summary and ratings history on Ocular Therapeutix click here. For more ratings news on Ocular Therapeutix click here.
Shares of Ocular Therapeutix closed at $10.73 yesterday.
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform
- Gordon Haskett Upgrades Wayfair (W) to Buy (1)
- Citi upgrades Coupang to Buy with $19 price target
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
